Class II โ€” Potential Health Hazard

Potential health hazard โ€” use of or exposure to this product may cause temporary or medically reversible adverse health consequences.

Sertraline Tablets Recalled by Legacy Pharmaceutical Packaging LLC Due to CGMP Deviations: Inadequate line clearance which may result...

Date: December 11, 2023
Company: Legacy Pharmaceutical Packaging LLC
Status: Ongoing
Source: FDA (Drug)

What You Should Do

Stop using this product immediately. Do not consume, use, or distribute it.

Return the product to the place of purchase for a full refund. If you have questions, contact Legacy Pharmaceutical Packaging LLC directly.

Affected Products

Sertraline Tablets, USP 100 mg, 30 tablets per bottle, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Cipla USA, Inc., Warren, NJ 07059, Packaged by: Legacy Pharmaceutical Packaging LLC., Earth City, MO 63045, NDC# 68645-523-54

Quantity: 161,664 bottles

Why Was This Recalled?

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Where Was This Sold?

This product was distributed to 2 states: AR, CA

Affected (2 states)Not affected

About Legacy Pharmaceutical Packaging LLC

Legacy Pharmaceutical Packaging LLC has 10 total recalls tracked by RecallDetector.

Related Recalls

Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report